ArticleScience advances2022

In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy.

Jeong Pil Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.